DURECT reports Q4/FY2023 results; larsucosterol shows mortality reduction in Phase 2b AH trial

DURECT CORP

Q4 2023 total revenues $2.7M, net loss $1.4M vs $3.3M and $10.5M in Q4 2022.
Full year 2023 revenues $8.5M, net loss $27.6M vs $19.3M and $35.3M in 2022; cash $29.8M.
Larsucosterol 30mg reduced 90-day mortality 41% (p=0.068); 90mg reduced 35% (p=0.124).
In U.S. patients, mortality reductions of 57% (30mg, p=0.014) and 58% (90mg, p=0.008).
Entered co-marketing agreement with Charles River for ALZET osmotic pumps in U.S./Canada.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DURECT CORP reported fourth quarter and full year 2023 results: revenue $2.7 million, net income net loss was $1.4 million.

Period: fourth quarter and full year 2023
Revenue: $2.7 million
Net income: net loss was $1.4 million
Result: reported results

Exact text from the filing

Total revenues were $2.7 million and net loss was $1.4 million for the three months ended December 31, 2023 compared to total revenues of $3.3 million and net loss of $10.5 million for the three months ended December 31, 2022. Total revenues were $8.5 million and net loss was $27.6 million for the year ended December 31, 2023, compared to total revenues of $19.3 million and net loss of $35.3 million for the year ended December 31, 2022.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-037198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.